Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519021 | 0.92 | KDR (0.51) | KDRKDM4EHTTALDH1A1MEN1 | |
| SCHEMBL15520447 | 0.87 | KDR (0.73) | KDREGFRMAPK14AURKBAURKA | |
| SCHEMBL15520326 | 0.87 | EGFR (0.66) | KDRALDH1A1EGFRLCKAURKB | |
| SCHEMBL15519461 | 0.84 | EGFR (0.46) | KDRALDH1A1EGFRLCKMAPK14 | |
| SCHEMBL15519686 | 0.84 | AURKA (0.53) | ALDH1A1MAPK1EGFRLMNAAURKB | |
| SCHEMBL15519919 | 0.84 | HDAC1 (0.68) | HTTMAPK1EGFRLMNAAURKB | |
| SCHEMBL15519463 | 0.83 | KDR (0.45) | KDRKDM4EHTTALDH1A1MEN1 | |
| SCHEMBL20782507 | 0.82 | HTT (0.69) | KDRKDM4EHTTALDH1A1MEN1 | |
| SCHEMBL15579869 | 0.82 | HDAC1 (0.56) | KDRKDM4EHTTALDH1A1MEN1 | |
| SCHEMBL15519478 | 0.80 | AURKB (0.61) | KDREGFRAURKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034886-B2 | 4-aminoquinazoline derivatives and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-05-19 | — | — | US | claimed |
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-08-21 | — | — | US | claimed |
| EP-2708532-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF | Jiangsu Hengyi Pharmaceutical Co.,Ltd (CN) | 2014-03-19 | — | — | EP | claimed |
| US-9034886-B2 | 4-aminoquinazoline derivatives and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-05-19 | — | — | US | disclosed |
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-08-21 | — | — | US | disclosed |
| EP-2708532-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF | Jiangsu Hengyi Pharmaceutical Co.,Ltd (CN) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | HDAC5, HDAC4, HDAC1 | KDR 4421/4885KDM4E 49/4885HTT 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.